Polycythemia Vera Medical Services in China

Polycythemia Vera (PV) is a chronic, clonal myeloproliferative neoplasm characterized by the overproduction of red blood cells (erythrocytosis), often accompanied by elevated white blood cell and platelet counts. It arises from a somatic gain-of-function mutation in the JAK2 gene—most commonly JAK2 V617F—in hematopoietic stem cells, leading to cytokine-independent activation of the JAK-STAT signaling pathway. This results in uncontrolled proliferation of erythroid precursors in the bone marrow, independent of erythropoietin (EPO) regulation. PV is not inherited but acquired, and while its exact triggers remain unclear, aging is the strongest known risk factor; the median age at diagnosis is 60–65 years. Epidemiologically, PV has an annual incidence of approximately 0.4–2.8 cases per 100,000 people, with a slight male predominance (male-to-female ratio ~1.3:1). It is rare in children and adolescents. Risk factors include advanced age, prior exposure to ionizing radiation (limited evidence), and possibly certain occupational chemical exposures—though no definitive environmental or lifestyle modifiable risks have been established. Untreated PV significantly increases the risk of life-threatening thrombotic events—including deep vein thrombosis, pulmonary embolism, myocardial infarction, and stroke—as well as hemorrhagic complications, transformation to myelofibrosis (5–15% over 15 years), and acute myeloid leukemia (1–2% over 10 years). Symptoms are often insidious and nonspecific: headache, dizziness, visual disturbances (e.g., scintillating scotoma), pruritus (especially after warm showers), erythromelalgia (burning pain in hands/feet), fatigue, early satiety, and splenomegaly-related left upper quadrant discomfort. Many patients are asymptomatic at diagnosis and identified incidentally via routine blood tests showing elevated hemoglobin (>16.5 g/dL in men, >16.0 g/dL in women), hematocrit (>49% in men, >48% in women), and/or red blood cell mass. Quality of life is frequently impaired—not only by physical symptoms but also by anxiety related to thrombotic risk, treatment burden (e.g., lifelong phlebotomy, medication adherence), and psychosocial impact of a chronic hematologic malignancy. Fatigue remains one of the most prevalent and debilitating patient-reported outcomes, even in well-controlled disease. Effective management aims to reduce thrombotic risk through cytoreduction, symptom control, and vigilant monitoring for disease progression. Early diagnosis and individualized, long-term care by specialized hematologists are essential to preserve survival (median overall survival exceeds 14–20 years with modern therapy) and maintain functional quality of life.

Polycythemia vera (PV) is a chronic, clonal myeloproliferative neoplasm characterized by autonomous overproduction of red blood cells, often accompanied by elevated white blood cell and platelet counts. Driven predominantly by the JAK2 V617F mutation (>95% of cases), PV carries significant risks of thrombosis, hemorrhage, myelofibrosis transformation, and acute leukemia. Management in the Department of Hematology focuses on risk stratification—based on age (>60 years) and prior thrombotic history—and tailoring interventions to reduce morbidity and mortality while preserving quality of life.

Conservative treatment forms the cornerstone of initial management, particularly for low-risk patients (age <60 years, no prior thrombosis). Phlebotomy remains first-line: regular venesection (typically 250–500 mL every 2–4 days initially) aims to maintain hematocrit <45% in men and <42% in women. This rapidly reduces blood viscosity, lowers thrombotic risk, and alleviates symptoms such as headache, dizziness, pruritus, and erythromelalgia. Aspirin (low-dose, 75–100 mg daily) is universally recommended for all PV patients without contraindications (e.g., active peptic ulcer disease or severe bleeding diathesis), as it significantly reduces microvascular complications—including transient ischemic attacks, digital ischemia, and ocular migraines—by inhibiting platelet cyclooxygenase-1. Lifestyle modifications are integral: smoking cessation is non-negotiable due to synergistic endothelial injury; hydration must be optimized to prevent hemoconcentration; and patients are counseled on early recognition of thrombotic symptoms (e.g., unilateral leg swelling, chest pain, sudden dysarthria) and hemorrhagic signs (e.g., prolonged epistaxis, petechiae).

Pharmacologic therapy is indicated for high-risk patients and those intolerant or refractory to phlebotomy alone. Hydroxyurea, a ribonucleotide reductase inhibitor, is the most widely used cytoreductive agent. It effectively controls hematocrit, leukocyte, and platelet counts, reduces splenomegaly, and lowers thrombotic incidence. Dosing is individualized (typically 500–2000 mg/day), with close monitoring of complete blood count and liver enzymes. Long-term safety is well-established, though rare concerns include cutaneous ulcers and potential (though unproven in large cohort studies) leukemogenicity after decades of use. For hydroxyurea-intolerant or resistant patients—or those with marked thrombocytosis (>1,500 × 10⁹/L) and microvascular symptoms—interferon-alpha (IFN-α), particularly pegylated formulations (peg-IFN-α-2a or -2b), offers a targeted, non-leukemogenic alternative. IFN-α induces molecular responses in up to 20–30% of patients (reduction in JAK2 V617F allele burden) and may modify disease biology. Ruxolitinib, a JAK1/JAK2 inhibitor, is FDA- and EMA-approved for hydroxyurea-resistant/intolerant PV. It provides robust control of splenomegaly and constitutional symptoms (fatigue, night sweats, weight loss) and improves hematocrit control, though it does not eliminate the malignant clone and requires vigilant monitoring for cytopenias and herpes zoster reactivation. Anagrelide may be added selectively for extreme thrombocytosis but is avoided as monotherapy due to increased arterial thrombosis risk and lack of benefit on erythrocytosis.

Surgical treatment has no primary role in PV management. Splenectomy is rarely performed—only in exceptional circumstances such as life-threatening portal vein thrombosis with massive, painful splenomegaly refractory to medical therapy—but carries high perioperative thrombotic and infectious risks and is associated with accelerated bone marrow fibrosis. Therefore, it is considered a last-resort palliative measure and is not part of standard guidelines. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only potentially curative modality but is reserved exclusively for select younger patients (<50–55 years) with progressive post-PV myelofibrosis or blast-phase transformation, given its substantial treatment-related mortality (15–30%) and morbidity. Its use in chronic-phase PV is not justified outside clinical trials due to favorable long-term survival with modern pharmacotherapy.

Treatment advantages in China reflect rapid integration of international standards with localized innovations. Major academic centers—including Peking University People’s Hospital, Shanghai Ruijin Hospital, and the First Affiliated Hospital of Sun Yat-sen University—offer comprehensive molecular diagnostics (JAK2/CALR/MPL sequencing, next-generation sequencing panels), standardized phlebotomy protocols, and access to biosimilar hydroxyurea and pegylated interferons at substantially lower cost than in Western markets. Notably, China’s National Medical Products Administration (NMPA) has approved ruxolitinib for PV since 2021, and real-world evidence from multicenter registries demonstrates comparable efficacy and safety to global data. Furthermore, China leads in digital health infrastructure: AI-powered decision support tools assist hematologists in dynamic risk assessment and treatment escalation, while telemonitoring platforms enable remote hematocrit tracking and symptom reporting—enhancing adherence and early intervention. Clinical trial participation is robust, with Chinese sites contributing significantly to pivotal phase III studies of novel agents (e.g., rusfertide, a hepcidin mimetic in late-stage development).

Recovery and long-term follow-up emphasize proactive, lifelong engagement. Patients require quarterly clinical assessments—including physical exam (spleen size), CBC, LDH, uric acid, and ferritin—plus annual bone marrow evaluation only if cytopenias, increasing splenomegaly, or worsening symptoms suggest progression. Iron deficiency induced by repeated phlebotomy must be monitored (serum ferritin <30 ng/mL warrants cautious iron supplementation only if symptomatic anemia develops, as excess iron may paradoxically stimulate erythropoiesis). Vaccination against influenza, pneumococcus, and hepatitis B is strongly encouraged due to immune dysregulation and splenic hypofunction in advanced disease. Psychosocial support is vital: chronic PV correlates with elevated anxiety and fatigue burden; multidisciplinary clinics increasingly incorporate psycho-oncology services and peer-led support networks. Finally, reproductive counseling is essential for premenopausal women—hydroxyurea is teratogenic, requiring contraception during treatment and for three months post-discontinuation; pregnancy necessitates transition to low-molecular-weight heparin and aspirin under joint hematology-obstetrics care. With contemporary risk-adapted strategies, median survival exceeds 20 years, underscoring that PV is a highly manageable chronic condition when managed by specialized hematologists within integrated, patient-centered systems.